Voyager Therapeutics (Nasdaq: VYGR) has entered into a new licensing agreement with Novartis (NOVN: VX), building on a partnership that began in March 2022.
The agreement covers use of a novel capsid from Voyager’s TRACER platform. The gene therapy program is targeting an undisclosed rare neurological disease.
Voyager will receive an upfront payment of $15 million and is eligible for up to $305 million in potential milestone payments and royalties.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze